|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
ISO |
Cabergoline results in increased expression of BDNF protein |
CTD |
PMID:35104500 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression |
ISO |
Cabergoline results in increased expression of CREB1 protein modified form |
CTD |
PMID:35104500 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
Cabergoline binds to and results in increased activity of DRD2 protein |
CTD |
PMID:35104500 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases expression increases secretion |
ISO |
cabergoline results in increased expression of GDNF mRNA cabergoline results in increased secretion of GDNF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Ngf |
nerve growth factor |
increases expression increases secretion |
ISO |
cabergoline results in increased expression of NGF mRNA cabergoline results in increased secretion of NGF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Prl |
prolactin |
decreases expression multiple interactions decreases secretion |
ISO EXP |
cabergoline results in decreased expression of PRL protein Haloperidol inhibits the reaction [cabergoline results in decreased secretion of PRL protein]; Sulpiride inhibits the reaction [cabergoline results in decreased secretion of PRL protein] |
CTD |
PMID:2570719 PMID:3745407 PMID:7670571 PMID:15377706 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression increases activity |
ISO |
chlorfluazuron results in increased expression of CYP2B6 mRNA chlorfluazuron results in increased activity of CYP2B6 protein |
CTD |
PMID:22310298 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions decreases activity |
ISO |
chlorfluazuron inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone] chlorfluazuron results in decreased activity of CYP2E1 protein |
CTD |
PMID:22634058 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
chlorfluazuron results in increased expression of CYP3A4 mRNA |
CTD |
PMID:22310298 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
EXP |
Diflubenzuron results in increased expression of CYP1A1 protein |
CTD |
PMID:8812189 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects binding |
ISO |
Diflubenzuron binds to CYP1A2 protein |
CTD |
PMID:32278787 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects binding |
ISO |
Diflubenzuron binds to CYP3A4 protein |
CTD |
PMID:32278787 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
Diflubenzuron results in increased expression of CYP3A23-3A1 protein |
CTD |
PMID:8812189 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
Diflubenzuron results in increased activity of NR1I2 protein |
CTD |
PMID:16565514 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
|
G |
Dhodh |
dihydroorotate dehydrogenase (quinone) |
multiple interactions increases metabolic processing increases oxidation |
ISO EXP |
2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]]; teriflunomide inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]]; Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; X 910279 inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]] DHODH protein results in increased metabolism of 4,5-dihydroorotic acid 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]]; azastene inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; brequinar inhibits the reaction [DHODH protein results in increased metabolism of 4,5-dihydroorotic acid]; brequinar inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; Ciprofloxacin inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; HR 325 inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; teriflunomide inhibits the reaction [DHODH protein results in increased metabolism of 4,5-dihydroorotic acid]; teriflunomide inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; teriflunomide inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]]; toltrazuril inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; X 910279 inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; X 910279 inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]] |
CTD |
PMID:9776318 PMID:9802339 PMID:11248707 |
|
NCBI chr19:37,551,858...37,573,327
Ensembl chr19:37,558,177...37,591,654
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
flufenoxuron results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [flufenoxuron results in increased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:33771252 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ar |
androgen receptor |
decreases expression |
ISO |
flufenoxuron results in decreased expression of AR mRNA |
CTD |
PMID:33771252 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases phosphorylation |
ISO |
flufenoxuron results in decreased phosphorylation of BAD protein |
CTD |
PMID:33771252 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
flufenoxuron results in increased expression of BAK1 protein |
CTD |
PMID:33771252 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
flufenoxuron results in decreased expression of BCL2L1 protein |
CTD |
PMID:33771252 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
ISO |
flufenoxuron results in increased expression of CYP17A1 mRNA |
CTD |
PMID:33771252 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression |
ISO |
flufenoxuron results in increased expression of CYP19A1 mRNA |
CTD |
PMID:33771252 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
flufenoxuron results in increased expression of DDIT3 protein |
CTD |
PMID:33771252 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
ISO |
flufenoxuron results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:33771252 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
increases expression |
ISO |
flufenoxuron results in increased expression of ERN1 protein |
CTD |
PMID:33771252 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
decreases expression |
ISO |
flufenoxuron results in decreased expression of HSD17B1 mRNA |
CTD |
PMID:33771252 |
|
NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
increases expression |
ISO |
flufenoxuron results in increased expression of HSD17B3 mRNA |
CTD |
PMID:33771252 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
increases expression |
ISO |
flufenoxuron results in increased expression of HSPA9 protein |
CTD |
PMID:33771252 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
flufenoxuron results in decreased expression of JUN mRNA |
CTD |
PMID:33771252 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
flufenoxuron results in decreased expression of JUND mRNA |
CTD |
PMID:33771252 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
flufenoxuron results in increased phosphorylation of MAPK1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:33771252 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:33771252 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO |
flufenoxuron results in increased phosphorylation of MAPK8 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK8 protein]; U 0126 inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:33771252 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
flufenoxuron results in decreased expression of PCNA protein |
CTD |
PMID:33771252 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Rmdn3 |
regulator of microtubule dynamics 3 |
increases expression |
ISO |
flufenoxuron results in increased expression of RMDN3 protein |
CTD |
PMID:33771252 |
|
NCBI chr 3:106,125,961...106,146,568
Ensembl chr 3:106,125,951...106,146,586
|
|
G |
Rps6ka1 |
ribosomal protein S6 kinase A1 |
multiple interactions decreases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [flufenoxuron results in decreased phosphorylation of RPS6KA1 protein]; U 0126 inhibits the reaction [flufenoxuron results in decreased phosphorylation of RPS6KA1 protein] |
CTD |
PMID:33771252 |
|
NCBI chr 5:146,079,018...146,118,272
Ensembl chr 5:146,079,021...146,118,272
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [flufenoxuron results in decreased phosphorylation of RPS6KB1 protein]; pyrazolanthrone affects the reaction [flufenoxuron results in decreased phosphorylation of RPS6KB1 protein]; U 0126 inhibits the reaction [flufenoxuron results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:33771252 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Sqstm1 |
sequestosome 1 |
increases phosphorylation |
ISO |
flufenoxuron results in increased phosphorylation of SQSTM1 protein |
CTD |
PMID:33771252 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression |
ISO |
flufenoxuron results in increased expression of STAR mRNA |
CTD |
PMID:33771252 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Vapb |
VAMP associated protein B and C |
increases expression |
ISO |
flufenoxuron results in increased expression of VAPB protein |
CTD |
PMID:33771252 |
|
NCBI chr 3:162,535,974...162,578,747
Ensembl chr 3:162,535,905...162,573,763
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
increases expression |
ISO |
flufenoxuron results in increased expression of VDAC1 protein |
CTD |
PMID:33771252 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions |
ISO |
glimepiride results in decreased activity of ABCB11 protein glimepiride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:20829430 PMID:23956101 PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
multiple interactions |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to glimepiride |
CTD |
PMID:22209866 |
|
NCBI chr 1:96,598,568...96,679,563
Ensembl chr 1:96,598,647...96,679,510
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity |
ISO |
glimepiride results in decreased activity of AKR1C1 protein |
CTD |
PMID:26362498 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
glimepiride results in decreased activity of AKR1C3 protein |
CTD |
PMID:26362498 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Capn1 |
calpain 1 |
increases expression |
ISO |
glimepiride results in increased expression of CAPN1 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn10 |
calpain 10 |
increases expression |
ISO |
glimepiride results in increased expression of CAPN10 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr 9:93,498,132...93,510,494
Ensembl chr 9:93,498,478...93,510,494
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
glimepiride results in increased expression of CAPN2 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression |
ISO |
glimepiride results in increased activity of CASP3 protein glimepiride results in increased expression of CASP3 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[glimepiride results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25455453 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
[Plant Extracts co-treated with glimepiride] inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]; glimepiride inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:26721197 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
decreases expression |
ISO |
glimepiride results in decreased expression of INS protein |
CTD |
PMID:15642492 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to glimepiride |
CTD |
PMID:22209866 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
glimepiride results in increased activity of NR1I2 protein [glimepiride results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
RT1-M3-1 |
RT1 class Ib, locus M3, gene 1 |
affects expression |
ISO |
glimepiride affects the expression of HLA-G mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
glimepiride affects the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; glimepiride affects the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:23121773 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
glimepiride inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; glimepiride inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:23121773 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
glimepiride results in increased expression of TP53 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Alb |
albumin |
decreases expression |
EXP |
hexafluoron results in decreased expression of ALB protein |
CTD |
PMID:34993831 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
hexafluoron results in increased expression of BAX mRNA |
CTD |
PMID:35773501 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
EXP |
hexafluoron results in decreased expression of BCL2 mRNA |
CTD |
PMID:35773501 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases expression |
EXP |
hexafluoron results in increased expression of CASP3 mRNA; hexafluoron results in increased expression of CASP3 protein |
CTD |
PMID:34993831 PMID:35773501 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
decreases activity |
EXP |
hexafluoron results in decreased activity of CAT protein |
CTD |
PMID:35773501 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases activity increases expression |
ISO |
hexafluoron results in increased activity of CYP2B6 protein hexafluoron results in increased expression of CYP2B6 mRNA |
CTD |
PMID:22310298 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
hexafluoron results in increased expression of CYP3A4 mRNA |
CTD |
PMID:22310298 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression |
EXP |
hexafluoron results in increased expression of GPT protein |
CTD |
PMID:34993831 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP |
hexafluoron results in increased expression of HMOX1 mRNA |
CTD |
PMID:34993831 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases expression |
EXP |
hexafluoron results in decreased expression of KEAP1 mRNA |
CTD |
PMID:34993831 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression |
EXP |
hexafluoron results in increased expression of MAPK8 mRNA |
CTD |
PMID:34993831 PMID:35773501 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
hexafluoron results in increased expression of TNF protein |
CTD |
PMID:34993831 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases response to substance |
ISO |
ACE2 gene SNP results in increased susceptibility to imidapril |
CTD |
PMID:27121444 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of and results in increased activity of imidapril; CES1 protein results in increased metabolism of and results in increased activity of imidapril; Dust inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril]; tert-butylphenyl diphenyl phosphate inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril]; triphenyl phosphate inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril] |
CTD |
PMID:9300133 PMID:31268531 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
affects response to substance |
ISO |
CYP11B2 gene polymorphism affects the susceptibility to imidapril |
CTD |
PMID:16765146 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
imidaprilat inhibits the reaction [AGT protein results in increased activity of and results in increased localization of PRKCA protein] |
CTD |
PMID:16257180 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
imidaprilat inhibits the reaction [AGT protein results in increased activity of and results in increased localization of PRKCA protein] |
CTD |
PMID:16257180 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
|
G |
Cat |
catalase |
increases activity |
ISO |
triflumuron results in increased activity of CAT protein |
CTD |
PMID:32312157 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases metabolic processing |
ISO |
CYP1A1 protein results in increased metabolism of triflumuron |
CTD |
PMID:31082524 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases metabolic processing |
ISO |
furafylline inhibits the reaction [CYP1A2 protein results in increased metabolism of triflumuron] |
CTD |
PMID:31082524 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases metabolic processing |
ISO |
CYP2B6 protein results in increased metabolism of triflumuron |
CTD |
PMID:31082524 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases metabolic processing |
ISO |
CYP2C18 protein results in increased metabolism of triflumuron |
CTD |
PMID:31082524 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions increases metabolic processing |
ISO |
Sulfaphenazole inhibits the reaction [CYP2C19 protein results in increased metabolism of triflumuron] |
CTD |
PMID:31082524 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases metabolic processing |
ISO |
CYP2C8 protein results in increased metabolism of triflumuron |
CTD |
PMID:31082524 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing |
ISO |
CYP2D6 protein results in increased metabolism of triflumuron |
CTD |
PMID:31082524 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases metabolic processing |
ISO |
Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of triflumuron] |
CTD |
PMID:31082524 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|